HRP20070360A2 - Pharmaceutical compositions comprising drospirenone - Google Patents
Pharmaceutical compositions comprising drospirenoneInfo
- Publication number
- HRP20070360A2 HRP20070360A2 HR20070360A HRP20070360A HRP20070360A2 HR P20070360 A2 HRP20070360 A2 HR P20070360A2 HR 20070360 A HR20070360 A HR 20070360A HR P20070360 A HRP20070360 A HR P20070360A HR P20070360 A2 HRP20070360 A2 HR P20070360A2
- Authority
- HR
- Croatia
- Prior art keywords
- menopause
- estrogen
- drospirenone
- active ingredient
- pharmaceutical composition
- Prior art date
Links
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 title abstract 2
- 229960004845 drospirenone Drugs 0.000 title abstract 2
- 229940011871 estrogen Drugs 0.000 abstract 3
- 239000000262 estrogen Substances 0.000 abstract 3
- 101000605827 Homo sapiens Pinin Proteins 0.000 abstract 2
- 102100038374 Pinin Human genes 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 abstract 1
- 206010030247 Oestrogen deficiency Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- METQSPRSQINEEU-OLKMEILKSA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3C3C4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-OLKMEILKSA-N 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 229960004766 estradiol valerate Drugs 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Farmaceutska kompozicija sadržava kao prvi aktivni sastojak estrogen, kao što je estradiol valerat,u dostatnoj količini za tretiranje smetnji i simptoma povezanih s deficijencijom endogenog nivoa estrogena u žena, a kao sekundarni aktivni sastojak 6ß;7ß;15ß;16ß-dimetilen-3-okso-17α-preg-4-ene-21,17-karbolakton (drospirenon, DRSP) u dostatnojkoličini za zaštitu endometrija od štetnog učinkaestrogena koji je koristan za drugo, tretiranje žena u peri-menopauzi, menopauzi i post-menopauzi. Ta kompozicija može se koristiti kao hormonska nadomjesna terapija i može se aplicirati kao multi-fazni farmaceutski pripravak. Kombinirana terapija može obuhvaćati kontinuiranu, sekvencijalnu ili prekidanu aplikaciju, ili njihovu kombinaciju, DRSP iestrogena, svaku po izboru u mikroniziranom obliku.The pharmaceutical composition comprises as a first active ingredient estrogen, such as estradiol valerate, in sufficient quantity to treat disorders and symptoms associated with endogenous estrogen deficiency in women, and as a secondary active ingredient 6ß; 7ß; 15ß; 16ß-dimethylene-3-oxo -17α-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient quantity to protect the endometrium from the deleterious effect of estrogen that is beneficial for another, treating women in peri-menopause, menopause and post-menopause. This composition can be used as a hormone replacement therapy and can be administered as a multi-phase pharmaceutical composition. Combination therapy may include continuous, sequential or discontinued administration, or a combination thereof, of DRSPs and estrogens, each optionally in micronized form.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32576000P | 2000-01-18 | 2000-01-18 | |
| EP00200183 | 2000-01-18 | ||
| PCT/IB2001/000041 WO2001052857A1 (en) | 2000-01-18 | 2001-01-18 | Drospirenone for hormone replacement therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20070360A2 true HRP20070360A2 (en) | 2008-12-31 |
| HRP20070360B1 HRP20070360B1 (en) | 2014-11-21 |
Family
ID=38170612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20070360AA HRP20070360B1 (en) | 2000-01-18 | 2007-08-17 | Pharmaceutical compositions comprising drospirenone |
Country Status (7)
| Country | Link |
|---|---|
| AR (1) | AR035633A1 (en) |
| CO (1) | CO5280075A1 (en) |
| HR (1) | HRP20070360B1 (en) |
| JO (1) | JO2334B1 (en) |
| PE (1) | PE20011051A1 (en) |
| SA (1) | SA01210754B1 (en) |
| UA (2) | UA89180C2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426601A1 (en) * | 1994-07-27 | 1996-02-01 | Schering Ag | Use of a combination product containing a competitive progesterone antagonist and a progestogen for the manufacture of a medicament for the treatment of endometriosis or Leiomyomata uteri |
| DE19654609A1 (en) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutic progestogens for the treatment of premenstrual dysphoric disorder |
| JP4354667B2 (en) * | 1999-08-31 | 2009-10-28 | バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト | Medicinal combination of ethinylestradiol and drospirenone for use as a contraceptive |
-
2001
- 2001-01-11 JO JO200110A patent/JO2334B1/en active
- 2001-01-15 PE PE2001000035A patent/PE20011051A1/en active IP Right Grant
- 2001-01-17 CO CO01003045A patent/CO5280075A1/en not_active Application Discontinuation
- 2001-01-17 AR ARP010100199 patent/AR035633A1/en not_active Application Discontinuation
- 2001-01-18 UA UAA200612100A patent/UA89180C2/en unknown
- 2001-01-18 UA UA2002086809A patent/UA81388C2/en unknown
- 2001-03-21 SA SA01210754A patent/SA01210754B1/en unknown
-
2007
- 2007-08-17 HR HRP20070360AA patent/HRP20070360B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| UA81388C2 (en) | 2008-01-10 |
| AR035633A1 (en) | 2004-06-23 |
| JO2334B1 (en) | 2006-06-28 |
| SA01210754B1 (en) | 2007-02-17 |
| UA89180C2 (en) | 2010-01-11 |
| CO5280075A1 (en) | 2003-05-30 |
| HRP20070360B1 (en) | 2014-11-21 |
| PE20011051A1 (en) | 2001-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00292B (en) | Drospirenone for hormone replacement therapy | |
| KR20090080989A (en) | USE OF ESTRADIOL VALERATE OR 17beta-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO | |
| NZ516502A (en) | Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG) | |
| JP2010508275A5 (en) | ||
| KR20060126671A (en) | Extended use combination comprising estrogens and progestins | |
| KR20120107492A (en) | Nestorone/estradiol transdermal gel | |
| KR970704450A (en) | Use of a progesterone antagonist and gestagen to treat endometrial hyperplasia or uterine leiomyoma (Use of a Progesterone Antagonist and a Gestagen for Endometriosis or Leiomyomate Uteri) | |
| TW200514560A (en) | Pharmaceutical formulation for contraception and hormone-replacement therapy | |
| CA2467237A1 (en) | Method of preventing or treating benign gynaecological disorders | |
| Samsioe | Transdermal hormone therapy: gels and patches | |
| EA200301022A1 (en) | HORMONAL REPLACEMENT THERAPY | |
| JP2011001388A (en) | Composition including combination of aromatase inhibitor, progestin and estrogen, and its use for the treatment of endometriosis | |
| TR199900764T2 (en) | A hormonal composition consisting of an estrogen compound and a progestational compound. | |
| HRP20070360A2 (en) | Pharmaceutical compositions comprising drospirenone | |
| HRP20020666A8 (en) | Drospirenone for hormone replacement therapy | |
| Verbost et al. | ORG 33628 and ORG 31710 to control vaginal bleeding in progestin-only contraceptive regimens | |
| CR6627A (en) | NEW CONTRACEPTIVE MEDICINAL PRODUCT AND ITS PREPARATION MODE | |
| KR19990087672A (en) | Sequential Estrogen / Progesterone Antagonist Formulation for Hormone Replacement Therapy | |
| US20010006963A1 (en) | Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women | |
| Whitehead | Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data | |
| Rozenberg | Clinical evidence supporting the rationale for constant oestrogen, intermittent progestogen hormone replacement therapy | |
| SI20851B (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
| AU713258B2 (en) | Once-a-month-injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women | |
| TH134365B (en) | Drospirinone for hormone replacement therapy | |
| TH134365A (en) | Drospirinone for hormone replacement therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: BAYER PHARMA AG, DE |
|
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190108 Year of fee payment: 19 |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20191227 Year of fee payment: 20 |
|
| PB20 | Patent expired after termination of 20 years |
Effective date: 20210118 |